期刊
JOURNAL OF THE KOREAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS
卷 47, 期 2, 页码 65-75出版社
KOREAN ACAD ORAL & MAXILLOFACIAL SURGERY
DOI: 10.5125/jkaoms.2021.47.2.65
关键词
Osteonecrosis; Bone regeneration; Mesenchymal stem cell; Cell therapy
Medication-related osteonecrosis of the jaw (MRONJ) is linked to the increased use of antiresorptive and anti-angiogenic drugs, but current treatments are unsatisfactory. Mesenchymal stem cells (MSCs) have shown potential in tissue regeneration and repair, with immunomodulatory properties that have been tested in animal models of MRONJ and specific clinical settings.
Medication-related osteonecrosis of the jaw (MRONJ) has recently associated to the increase in antiresorptive and anti-angiogenic drugs prescriptions in the treatment of oncologic and osteoporotic patients. The physiopathogenesis of MRONJ remains unclear and available treatments are unsatisfactory. Newer pharmacological treatments have shown good results, but are not curative and could have major side effects. At the same time as pharmacological treatments, mesenchymal stem cells (MSCs) have emerged as a promising therapeutic modality for tissue regeneration and repair. MSCs are multi-potential non-hematopoietic progenitor cells capable to differentiating into multiple lineages of the mesenchyme. Bone marrow MSCs can differentiate into osteogenic cells and display immunological properties and secrete paracrine anti-inflammatory factors in damaged tissues. The immunomodulatory, reparative, and anti-inflammatory properties of bone marrow MSCs have been tested in a variety of animal models of MRONJ and applied in specific clinical settings. The aim of this review is to discuss critically the immunogenicity and immunomodulatory properties of MSCs, both in vitro and in vivo, the possible underlying mechanisms of their effects, and their potential clinical use as modulators of immune responses in MRONJ, and to identify clinical safety and recommendations for future research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据